The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: The HEMA e-Chart project

Haematologica

Volumn 96, Issue 9, 2011, Pages 1366-1370

  Pagano, Livio ^a   Caira, Morena ^a   Nosari, Annamaria ^b   Cattaneo, Chiara ^c   Fanci, Rosa ^d   Bonini, Alessandro ^e   Vianelli, Nicola ^f   Garzia, Maria Grazia ^g   Mancinelli, Mario ^a   Tosti, Maria Elena ^h   Tumbarello, Mario ^a   Viale, Pierluigi ^f   Aversa, Franco ⁱ   Rossi, Giuseppe ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c SPEDALI CIVILI   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e Divisione di Ematologia   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h ISTITUTO SUPERIORE DI SANITÀ   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Empirical antifungal therapy; Hematologic malignancies; Pre emptive antifungal therapy

Indexed keywords

AMPHOTERICIN B DERIVATIVE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MORTALITY; MYCOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; YOUNG ADULT;

EID: 80052355809     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.042598     Document Type: Article

References (20)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7): 909-17.
2. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-60.
3. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropenic cancer patients with persistent fever. Eur J Cancer. 2007;S5:32-42.
4. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8): 1042-51.
5. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242-50.
6. Penack O, Rempf P, Graf B, Blau IW, Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol. 2008;19(5): 984-9.
7. Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, et al. A prospective randomized controlled trial comparing PCRbased and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant. 2009;43(7): 553-61.
8. Pagano L, Caira M, Nosari A, Rossi G, Viale P, Locatelli F, Aversa F. Hema e-Chart: Italian Registry for prospective analysis of epidemiology, management and outcome of febrile events in patients with hematological malignancies. J Chemother. 2010;22 (1):20-4.
9. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21.
10. Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Burgio VL, Mandelli F. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer. 1989;64(10):2030-4.
11. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751-8.
12. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer. 2008;112(10):2309-12.
13. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982; 72(1):101-11.
14. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3): 373-9.
15. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340(10): 764-71.
16. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346 (4):225-34.
17. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391-402.
18. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28(4):667-74.
19. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant. 2011;16(5):709-18.
20. de Pauw BE, Donnelly JP Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? Clin Infect Dis. 2009;48(8): 1052-4.